3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Not yet recruiting
1
Completed
1
Sponsor Class
NETWORK
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
12
Recurrence
2
Immunoglobulin Light-chain Amyloidosis
2
Plasmablastic Lymphoma
1
Neoplasms, Plasma Cell
1
Amyloidosis
1
Interventions
Dexamethasone
23
Melphalan
18
Cyclophosphamide
12
Filgrastim
10
Bortezomib
10
Calcium Dobesilate
8
Peripheral Blood Stem Cell Transplantation
7
daratumumab
6
Lenalidomide
6
pomalidomide
5
dexamethasone acetate
3
birtamimab
3
Thalidomide
3
Radiotherapy
3
Interferon-alpha
3
Granulocyte Colony-Stimulating Factor
3
sargramostim
2
isatuximab
2
dexamethasone 21-phosphate
2
belantamab mafodotin
2
Focal Adhesion Protein-Tyrosine Kinases
2
Etoposide
2
Epoetin Alfa
2
Doxycycline
2
Busulfan
2
siltuximab
1
pegfilgrastim
1
ixazomib
1
fludarabine phosphate
1
elotuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Immunoglobulin Light-chain Amyloidosis
×
belantamab mafodotin
×
Clear all
NCT07224672
2026-03-17
ALANIS
GlaxoSmithKline
Phase 2
Not yet recruiting
60 enrolled
NCT04617925
2025-09-05
EMN27
European Myeloma Network B.V.
Phase 2
Completed
35 enrolled